Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 10, 2014

Primary Completion Date

February 23, 2015

Study Completion Date

February 23, 2015

Conditions
Colitis, Ulcerative
Interventions
DRUG

GSK3050002

GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.

DRUG

Placebo

Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY